---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-218690"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2021-07-19T23:59:59+00:00"
generated_at: "2026-06-30T04:30:48.027916+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics appoints Martin Babler as Class II director, effective July 19, 2021

## Summary
- Martin Babler appointed to Board as Class II director and Audit Committee member, effective July 19, 2021.
- Babler previously President and CEO of Principia Biopharma until its acquisition by Sanofi in October 2020.
- Received non-incentive stock options for 36,400 shares vesting monthly over three years under 2020 Equity Incentive Plan.
- Will receive standard non-employee director compensation and enter into customary indemnity agreement.

## SEC filing metadata
- accession: 0001193125-21-218690
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2021-07-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000119312521218690/0001193125-21-218690-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000119312521218690/d172272d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-218690
- JSON: https://secwatch.observer/filing/0001193125-21-218690.json
- Plain text: https://secwatch.observer/filing/0001193125-21-218690.txt

## Key facts
- Executive change
  Martin Babler was appointed as Class II director at Prelude Therapeutics Inc.
  - Action: appointed
  - Role: Class II director
  source text: the Board appointed Martin Babler as a Class II director and as a member of the Audit Committee of the Board, effective as of July 19, 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000119312521218690/0001193125-21-218690-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.